Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Genitourinary 2Gastrointestinal 2Classical hematology 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Breast Neoplasms 2Early Stage Breast Cancer 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Ciprofloxacin × Breast × Clear all
NCT02816112 2020-05-27

REaCT-TC2

Ottawa Hospital Research Institute

Phase 4 Completed
458 enrolled
Breast

Early Stage Breast Cancer

NCT02173262 2017-11-06

OTT14-03

Ottawa Hospital Research Institute

Phase 4 Completed
142 enrolled
Breast

Breast Neoplasms

NCT00590785 2017-08-25

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

National Cancer Institute (NCI)

Phase 3 Completed
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡